一个多中心研究的当代长期Tafamidis结果在Transthyretin Amyloid心肌病变
Ahmad Masri1, Priyanka Bhattacharya2, Brent Medoff3
1Amyloidosis Center, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, USA.
JACC. CardioOncology
|April 17, 2025
概括
在一个真实世界的研究中,对Transthyretin amyloid心肌病 (ATTR-CM) 的Tafamidis治疗显示了43个月的39%的死亡率. 需要进一步的研究来提高ATTR-CM患者的生存率.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 塔法米迪斯在转氨基氨基酸心肌病 (ATTR-CM) 的ATTR-ACT试验中显示出生存益处和减少住院治疗.
- 由于ATTR-CM的识别和早期诊断的增加,ATTR-CM的流行病学正在发展.
研究的目的:
- 评估接受tafamidis的ATTR-CM患者当代的长期结果.
- 在现实环境中评估tafamidis的有效性.
主要方法:
- 分析了在2018-2021年期间在美国5个中心接受tafamidis的624名ATTR-CM患者的队列.
- 主要结局是全因死亡率,随访时间中位数为43.2个月.
主要成果:
- 38.6%的患者在43.2个月的中位随访期内死亡.
- 在65个月后仍然活着的概率为54.1%.
- 在诊断后6个月内接受治疗的患者中观察到类似的生存概率.
结论:
- 接受tafamidis治疗的ATTR-CM患者在43个月的中位数中死亡率为39%.
- 更好地了解ATTR-CM自然史和增强的治疗策略对于改善存活率和管理心力衰竭进展至关重要.
相关概念视频
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


